Basiliximab Does Not Impair Airway Mucociliary Clearance of Rats

Previous studies have shown that immunosuppressive drugs impair the airway mucociliary clearance of rats. However, considering the high specificity of basiliximab (BSX) and the absence of studies reporting its side effects, our aim was to investigate whether BSX, associated or not with triple therapy, impairs the mucociliary system. Forty rats were divided into 4 groups: Control, BSX, Triple, and BSX + Triple. After 15 days of treatment, animals were euthanized and the ciliary beating frequency (CBF), mucociliary transport velocity (MCTV), neutral and acid mucin production, Muc5ac and Muc5b gene expression, inflammatory cell number, and interleukin (IL)-6 concentration were analyzed. CBF and MCTV were lower in Triple and BSX + Triple groups ( p < 0.05). Neutral mucin percentage was higher in Triple group ( p < 0.05), and acid mucin percentage was higher in Triple and BSX + Triple groups ( p < 0.05). The Muc5ac and Muc5b gene expression was higher in Triple and BSX + Triple groups ( p < 0.05). Animals from Triple and BSX + Triple groups presented fewer mononuclear cells ( p < 0.05). The number of polymorphonuclear cells was higher in the Triple group ( p < 0.05). In the analysis of inflammatory cells in the blood, there was a decrease in lymphocytes and an increase in neutrophils in the Triple and BSX + Triple groups ( p < 0.05). The concentration of IL-6 significantly increased in the animals of the Triple and BSX + Triple groups ( p < 0.05). BSX did not change the mucociliary apparatus of rats.